Intraoperative Telemedicine Program: ACTFAST-3 Study

By Staff Writer

September 28, 2023

Introduction to the ACTFAST-3 Study

The Anesthesiology Control Tower (ACT), a real-time telemedicine decision support system, was tested in the ACTFAST-3 Randomised Clinical Trial. The study aimed to evaluate the feasibility of the ACT and its impact on two quality of care measures: postoperative hypothermia and hyperglycemia.

The ACTFAST-3 study, a single-centre pilot superiority RCT, took place in the USA from April 2017 to June 2019. The study involved all patients aged 18 years and above who had undergone surgery. However, the study did not include patients if the ACT staff did not staff more than 50% of their case duration or if they did not suffer from diabetes (for glycemic outcomes).

Results and Implications

The pilot study, involving 26,254 patients, found that the telemedicine decision support intervention did not significantly alter the two quality of care outcomes. While there was a slight increase in intraoperative glucose measurement in the intervention group, there was no difference in the frequency of treatment for hyperglycemia. This lack of difference could explain the unchanged postoperative hyperglycemia rates.



The study also highlighted potential reasons for these results. For instance, the high adherence to each measure at baseline made significant improvements challenging. Also, the trial noted the impact of the Hawthorne effect, where changes in behaviour occur due to the awareness of being observed.

The study concluded that further optimization of clinical decision support and workflows might help the intraoperative telemedicine program achieve improvement in targeted clinical measures.

Conclusion:

The ACTFAST-3 study offers crucial insights into the application of telemedicine in anesthesiology, yet it underscores the complexity of enhancing care quality through such interventions. Despite the implementation of the Anesthesiology Control Tower, improvements in postoperative hypothermia and hyperglycemia were not evident. This outcome suggests that high baseline adherence to quality measures and behavioural modifications due to the Hawthorne effect may dilute the impact of telemedicine interventions. Consequently, to realise the potential benefits of real-time decision support systems, we must refine clinical support tools and streamline operative workflows. The findings prompt a re-evaluation of strategies within the telemedicine framework to ensure that technological advancements translate into tangible improvements in patient care. 

Reference url

Recent Posts

Trump healthcare policy changes
    

Trump Healthcare Policy Changes: Reversing Biden’s Executive Orders and WHO Withdrawal

🚨 *What does Trump’s latest healthcare policy shift mean for the future of U.S. health initiatives?*
In a bold move, President Trump has reversed key Biden-era healthcare directives, altering approaches to COVID-19, drug pricing, and international health partnerships. This could reshape our healthcare landscape significantly. Dive into the article to understand how these changes could impact patients, providers, and the industry at large!

#SyenzaNews #healthcare #healthcarepolicy #innovation

U.S. withdraws from WHO
     

U.S. Withdraws from WHO: Impact on Global Health Security and Relations

🚨 *What does the U.S. withdrawing from the WHO mean for global health?*
President Trump’s executive order to begin the withdrawal process raises serious concerns about the future of global health security. From financial disparities to a shift in international partnerships, the implications could reshape our collective ability to combat pandemics and health crises.

Dive into our article to understand the potential impacts on health outcomes and the quest for new alliances.

#SyenzaNews #globalhealth #healthcarepolicy

semaglutide NAION risk
    

Semaglutide NAION Risk: EMA Review Initiated Amid Conflicting Evidence

🔍 Is semaglutide linked to vision loss?

The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.

Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!

#SyenzaNews #Pharmaceuticals #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.